Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Follow-Up Study of Participants Treated With the Lentiviral-Based Genetically Modified, Autologous Cell Product, AGT103-T

NCT05529342 is registered in ClinicalTrials.gov with American Gene Technologies International Inc. as lead sponsor.

NCT NCT05529342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05529342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Follow-Up Study of Participants Treated With the Lentiviral-Based Genetically Modified, Autologous Cell Product, AGT103-T
Lead sponsor
American Gene Technologies International Inc.
Phase
Observational
Overall status
Enrolling by invitation
Start date
August 29, 2022
Completion date
September 29, 2038
Enrollment
7 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv